Combined action of Silymarin and Celecoxib in modulating inflammatory mediators in osteoarthritis

Z. Ashkavand , H. Malekinejad , B.S. Vishwanath
{"title":"Combined action of Silymarin and Celecoxib in modulating inflammatory mediators in osteoarthritis","authors":"Z. Ashkavand ,&nbsp;H. Malekinejad ,&nbsp;B.S. Vishwanath","doi":"10.1016/j.bionut.2014.07.007","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>Inflammation is the hallmark of osteoarthritis (OA) leading to pain and disability. Objective of this investigation was to evaluate the effect of </span>Silymarin<span><span> (SMN, an antioxidant), Celecoxib (CLX, a selective COX inhibitor) and their combination on chemically induced arthritis in rats. The biochemical parameters and </span>radiology<span> impact of the treatment was also determined. Wistar male rats were assigned into five groups including control, OA</span></span></span><sup>+</sup>, OA<sup>+</sup> CLX (100<!--> <!-->mg/kg), OA<sup>+</sup> SMN (50<!--> <!-->mg/kg) and OA<sup>+</sup> CLX<!--> <!-->+<!--> <!-->SMN (25<!--> <span><span>mg/kg). Combined treatment returned the elevated levels of inflammatory mediators (ROS, TNF-α, </span>ALP, COX-2) to normal levels in 14</span> <!-->days. In the SMN<!--> <!-->+<!--> <!-->CLX treated animals significant reduction in KL grade and normal joint space narrowing was observed. X-ray radiological studies supported the biochemical findings. These findings suggest that co-administration of SMN with CLX could be an effective antiarthritic treatment which can equally abolish the arthritis associated secondary complication.</p></div>","PeriodicalId":100182,"journal":{"name":"Biomedicine & Preventive Nutrition","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bionut.2014.07.007","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedicine & Preventive Nutrition","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2210523914000671","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Inflammation is the hallmark of osteoarthritis (OA) leading to pain and disability. Objective of this investigation was to evaluate the effect of Silymarin (SMN, an antioxidant), Celecoxib (CLX, a selective COX inhibitor) and their combination on chemically induced arthritis in rats. The biochemical parameters and radiology impact of the treatment was also determined. Wistar male rats were assigned into five groups including control, OA+, OA+ CLX (100 mg/kg), OA+ SMN (50 mg/kg) and OA+ CLX + SMN (25 mg/kg). Combined treatment returned the elevated levels of inflammatory mediators (ROS, TNF-α, ALP, COX-2) to normal levels in 14 days. In the SMN + CLX treated animals significant reduction in KL grade and normal joint space narrowing was observed. X-ray radiological studies supported the biochemical findings. These findings suggest that co-administration of SMN with CLX could be an effective antiarthritic treatment which can equally abolish the arthritis associated secondary complication.

水飞蓟素和塞来昔布在骨关节炎炎症介质调节中的联合作用
炎症是导致疼痛和残疾的骨关节炎(OA)的标志。目的探讨水飞蓟素(SMN,一种抗氧化剂)、塞来昔布(CLX,一种选择性COX抑制剂)及其联合用药对化学诱导大鼠关节炎的影响。测定了治疗的生化参数和放射学影响。Wistar雄性大鼠分为对照组、OA+、OA+ CLX (100 mg/kg)、OA+ SMN (50 mg/kg)和OA+ CLX + SMN (25 mg/kg) 5组。联合治疗14天后,升高的炎症介质(ROS、TNF-α、ALP、COX-2)水平恢复正常。在SMN + CLX治疗的动物中,观察到KL等级显著降低和正常关节间隙狭窄。x射线放射学研究证实了这一生化发现。这些发现表明SMN与CLX联合使用可能是一种有效的抗关节炎治疗方法,同样可以消除关节炎相关的继发并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信